Panel doubts agents' role in improving Alzheimer's diagnosis

01/30/2013 | Reuters

The Medicare Evidence Development & Coverage Advisory Committee showed a lack of confidence in the use of imaging agents to detect brain plaques linked to Alzheimer's disease risk. Only one of the 12 voting members expressed intermediate to high confidence that the agents will help improve outcomes in patients showing early signs of memory problems. This lack of confidence may lead to CMS reimbursement problems for Eli Lilly & Co.'s FDA-approved imaging agent Amyvid. Lilly said it is confident of the usefulness of its product in evaluating patients suspected of having Alzheimer's.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC